TMCnet - World's Largest Communications and Technology Community



T2 Biosystems Presents New Data at the Thrombosis and Hemostasis Summit of North America Demonstrating Ability of T2MR Platform Technology to Measure Platelet Activity and Additional Hemostasis Parameters
[April 10, 2014]

T2 Biosystems Presents New Data at the Thrombosis and Hemostasis Summit of North America Demonstrating Ability of T2MR Platform Technology to Measure Platelet Activity and Additional Hemostasis Parameters

LEXINGTON, Mass. --(Business Wire)--

T2 Biosystems, a company developing direct detection products designed to enable superior diagnostics, today announced the presentation of data highlighting the role of its T2MR platform technology in measuring platelet function, an important parameter in assessing hemostasis and thrombosis. The company will also present data on the use of T2MR to deliver multiplex hemostasis results that include clotting time and fibrinogen generated by the company's investigational T2Stat instrument and T2HemoStat panel, which run on the T2MR platform. The T2Stat instrument and T2HemoStat panel are currently under development for the potential identification and management of patients suspected of bleeding disorders, such as the acute coagulopathy of trauma. The data will be presented at the Thrombosis and Hemostasis Summit of North America (THSNA), being held in Chicago, IL April 10-12, 2014.

The research being presented at THSNA builds on previous studies related to T2MR with an expanded data set that shows significant correlation of platelet activity measurement with light transmission aggregometry (LTA), the current clinical standard for platelet function testing. This correlation was achieved on a T2Stat instrument using a small volume (36 ┬Ál) of whole blood with no need for sample preparation, whereas performing the LTA assay required highly trained laboratory professionals, up to 25 mL of blood, and significant sample manipulation and hands-on time. The T2HemoStat assay, using T2MR technology, provided a result in approximately 20 minutes compared to a minimum of 1.5 hours to more than a day for LTA.

"The ability to rapidly identify bleeding disorders and monitor hemostasis in trauma ptients could provide clinicians with critical information to save lives and improve the quality and costs of patient care," said Mitchell Cohen, MD, Director of Trauma Research at San Francisco General Hospital. "The challenge with existing approaches to monitoring these patients is that multiple test results from several different instruments are required, many of which are time-consuming, complex and usually restricted to specialized laboratories. This process often takes too long, leading to delays in treatment that can impact the health of the patient. This data provides evidence of excellent correlation of T2MR with the lengthy and complex gold standard of LTA and further supports the potential of this technology to address the limitations of the current standard of care."

Each year in the United States, more than three million patients present with trauma and signs of impaired hemostasis (the process that causes bleeding to stop). These patients require rapid and frequent assessments to guide clinical decisions regarding the appropriate blood products, therapies and surgical interventions needed to balance their fluctuating hemostasis state. The investigational T2HemoStat panel is designed to characterize multiple critical hematologic factors, including platelet function, coagulation and fibrinolysis, using very small samples of whole blood on a single T2Stat instrument within 20 minutes, allowing for more informed treatment decisions in high-intensity trauma settings.

"T2 Biosystems is committed to demonstrating the potential value of our T2MR technology platform through the development of diagnostic tests that may impact clinical decision-making to improve the health of the patient and reduce the costs of healthcare," said John McDonough, President and Chief Executive Officer of T2 Biosystems. "The data presented at THSNA provides further evidence of the potential for T2MR technology to make hemostasis testing accessible to healthcare professionals in a variety of care settings, and to provide clinically valuable, rapid and reliable insights into platelet function and other hemostasis measurements."

About T2 Biosystems

T2 Biosystems is developing clinical diagnostics powered by T2MR, a significant advance in detection technology that is designed to deliver superior sensitivity quickly to guide more effective clinical decision-making. T2 Bio is developing a pipeline of molecular diagnostics and hemostasis products focused on conditions where rapid and accurate results may have a significant impact on patients' lives and healthcare costs. The Company's lead products under development, the T2Candida and T2Bacteria panels, are designed to identify life-threatening pathogens associated with sepsis directly from whole blood in a matter of hours, compared to the two to five days required with blood culture.

T2Candida is for investigational use only. The performance characteristics of this product have not been established.

T2HemoStat, T2Stat, and T2Bacteria are for Research Use Only. They are not intended for use in diagnostic procedures.

T2 Biosystems®, T2MR®, T2Candida® are registered trademarks of T2 Biosystems, Inc.

T2HemoStat™, T2Stat™, and T2Bacteria™ are trademarks of T2 Biosystems, Inc.

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy